Shares of Alkermes Plc (NASDAQ:ALKS) fell nearly 20 percent in early Monday trading after the FDA stunned the company with a Refusal to …
As the healthcare community debates the positive top line results from Alkermes Plc (NASDAQ:ALKS) FORWARD-5 study for ALKS 5461 in major depressive disorder, Credit Suisse analyst …
Alkermes Plc All eyes today on Alkermes Plc (NASDAQ:ALKS) as the biopharmaceutical company announced positive phase 3 data for ALKS 5461, a pipeline drug …
Alkermes Plc (NASDAQ:ALKS) investors have a smile on their faces Thursday evening, after the drug maker announced positive topline results from its FORWARD-5, the third core efficacy trial …
In a research report published Tuesday afternoon, J.P.